Chapter 1. Research Scope and Methodology
1.1 Market Definition
1.2 Research Scope
1.2.1 Market segmentation by drug
1.2.2 Market segmentation by mechanism of action (MoA)
1.3 Research Methodology and Sources
Chapter 2. Executive Summary
2.1 Key Findings
2.2 Research Summary
Chapter 3. Market Outlook
3.1 Introduction
3.2 Trends in the Global PD-1 & PD-L1 Inhibitors Market
3.3 Opportunities in the Global PD-1 & PD-L1 inhibitor market
3.4 Factors Driving Growth of the Market and its Impact on Market Forecast
3.5 Factors Hindering the Growth of the Market and its Impact on Market Forecast
Chapter 4. Global PD-1 & PD-L1 Inhibitors Pipeline Analysis
4.1 Overview
4.4.1 Pipeline Analysis by MOA
4.4.2 Pipeline Analysis by Molecule type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company
Chapter 5. Global PD-1 & PD-L1 Inhibitors Pipeline Analysis by Phase (2016)
5.1 Filed: Drug profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase III: Drug profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase II: Drug profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Phase I: Drug profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Clinical Trials
5.4.4 Clinical Results
5.4.5 Strategic Development
5.4.6 Designation
5.4.7 Grants
5.4.8 Patent
5.4.9 Technology
5.5 Pre-Clinical: Drug profiles
5.5.1 Pre-Clinical Study
5.5.2 Pre-Clinical Results
5.5.3 Strategic Development
5.5.4 Designation
5.5.5 Grants
5.5.6 Patent
5.5.7 Technology
Chapter 6 Competitive Landscape
6.1 SWOT Analysis of PD-1 and PD-L1 Inhibitors
Chapter 7 Global PD-1 & PD-L1 Inhibitors Market Size and Forecast (2015 - 2025)
7.1 Global PD-1 & PD-L1 inhibitors Market, by Drug
7.2 Global PD-1 & PD-L1 Inhibitors Market, by Mechanism of Action (MoA)
Chapter 8 Global PD-1 & PD-L1 Inhibitors Market, by Drug
8.1 Opdivo (Nivolumab) Market
8.2 Keytruda (Pembrolizumab) Market
8.3 Tecentriq (Atezolizumab) Market
8.4 Durvalumab Market
8.5 Avelumab Market
Chapter 9. Global PD-1 & PD-L1 Inhibitors Market, by Mechanism of Action (MoA)
9.1 PD-1 Inhibitor Market
9.2 PD-L1 Inhibitor Market
Chapter 10. Competitive Analysis
10.1 Porter’s Five Forces of Competitive Position Analysis
10.2 Market Share Analysis of Key Players
Chapter 11. Company Profiles and Strategic Developments
Chapter 12. Appendix
LIST OF TABLES
SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SNAPSHOT
ANTI-PD-1 COMBINATIONS WITH MONOCLONAL ANTIBODIES OR OTHER IMMUNO-ONCOLOGY AGENTS
ANTI-PD-L1 COMBINATIONS WITH MONOCLONAL ANTIBODIES OR OTHER IMMUNO-ONCOLOGY AGENTS
ANTI PD-1 & PD-L1 MAB COMBINATIONS WITH VACCINES
ANTI PD-1 & PD-L1 MAB COMBINED WITH GENE AND CELL THERAPIES AND OTHER NOVEL APPROACHES
DIFFERENT DRUG DESIGNATION FOR PD-1 & PD-L1 INHIBITORS
DRIVERS FOR THE MARKET: IMPACT ANALYSIS
RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
PIPELINE ANALYSIS OF PD-1 & PD-L1 INHIBITORS, BY COMPANY (2016)
DESCRIPTION OF FILED DRUG CANDIDATES
CLINICAL TRIALS OF FILED DRUG CANDIDATES
DESCRIPTION OF PHASE III DRUG CANDIDATES
CLINICAL TRIALS OF PHASE III DRUG CANDIDATES
DESCRIPTION OF PHASE II DRUG CANDIDATES
CLINICAL TRIALS OF PHASE II DRUG CANDIDATES
DESCRIPTION OF PHASE I DRUG CANDIDATES
CLINICAL TRIALS OF PHASE I DRUG CANDIDATES
DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES
SWOT ANALYSIS OF BACE INHIBITORS PIPELINE
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2014 – 2016)
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2017 – 2025)
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2014 – 2016)
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2017 – 2025)
GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2014 – 2016)
GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2017 – 2025)
COMPANIES- AT A GLANCE
LIST OF FIGURES
RESEARCH SCOPE FOR GLOBAL PD-1 & PD-L1 INHIBITORS MARKET
RESEARCH METHODOLOGY FOR GLOBAL PD-1 & PD-L1 INHIBITORS MARKET
DEACTIVATED T CELL IN PD-1 AND PD-L1
ACTIVATED T CELL IN PD-1 AND PD-L1 INHIBITORS
GLOBAL DEATHS CAUSED BY CANCER (2012)
NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR PD-1 AND PD-L1 INHIBITORS (2016)
GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY MECHANISM OF ACTION (2016)
GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY MOLECULE TYPE (2016)
GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2016)
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, $M (2014 – 2025)
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2014 – 2025)
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SPLIT, BY DRUG (2016)
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2014 – 2025)
GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SPLIT, BY MOA (2016)
GLOBAL OPDIVO MARKET, $M (2014 – 2025)
GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2014 – 2025)
GLOBAL OPDIVO MARKET SPLIT, BY COUNTRY (2016)
GLOBAL KEYTRUDA MARKET, $M (2014 – 2025)
GLOBAL TECENTRIQ MARKET, $M (2014 – 2025)
GLOBAL DURVALUMAB MARKET, $M (2014 – 2025)
GLOBAL AVELUMAB MARKET, $M (2014 – 2025)
GLOBAL PD-1 INHIBITOR MARKET, $M (2014 – 2025)
GLOBAL PD-L1 INHIBITOR MARKET, $M (2014 – 2025)
PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS
MARKET SHARE ANALYSIS OF KEY PLAYERS (2016)
MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)
